Astrana Health's Earnings Growth Potential Through RAF Score Enhancement: A Buy Rating Analysis
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Baird Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $67
Astrana Health Analyst Ratings
Baird Maintains Outperform on Astrana Health, Raises Price Target to $67
Astrana Health Analyst Ratings
Truist Securities Raises Price Target on Astrana Health to $59 From $50, Maintains Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Astrana Health (ASTH)
Astrana Health's Strong Q2 Performance and Strategic Growth Fuel Buy Rating
Astrana Health Analyst Ratings
Stifel Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $60
Jefferies Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $62
Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Astrana Health (ASTH)
Lake Street Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and REPRO-MED Systems (KRMD)
Astrana Health Analyst Ratings
Truist Securities Upgrades Astrana Health to Buy, Raises Price Target to $50
Astrana Health (ASTH) Gets a Buy From Lake Street
Astrana Health Analyst Ratings